Esperion Therapeutics, Inc. (ESPR)
| Previous close | 2.1200 |
| Open | 2.3850 |
| Bid | 2.3200 x 200 |
| Ask | 2.4500 x 200 |
| Day's range | 2.1300 - 2.5000 |
| 52-week range | 0.7000 - 3.4000 |
| Volume | |
| Avg. volume | 6,095,429 |
| Market cap | 452.668M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0300 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.41 |
- GuruFocus.com
Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase
Significant Growth and FDA Approvals Propel Performance
ZacksEsperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireEsperion Reports First Quarter 2024 Financial Results
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non-Statins to Prevent Heart Attacks
